Cambridge, MA, February 04, 2008 --(PR.com
)-- Harry Glorikian will be providing Chairperson’s remarks ahead of a series of seminars concerning Future Trends in Molecular Diagnostics scheduled from 8:30am until 12:00pm PST on March 28, 2008.
Prior to the onset of molecular diagnostics, the diagnosis and prognosis of disease states and infections would be categorized according to cell pathology under a microscope while the accurate detection of a patient’s disease susceptibility was an impossibility. Molecular diagnostics now plays a crucial role in the development of personalized medicine by identifying the underlying molecular defects in infections and diseases through use of mass spectrometry and micro-array technology. It is currently the fastest growing segment of the entire in vitro diagnostics market.
Harry Glorikian’s experience allows him to intellectually address a broad range of areas within life sciences. His direct experience in sales, marketing, business development, and intellectual property combined with his technical and market knowledge provides both a unique and insightful perspective. Harry has more than 15 years of experience in the life science industry, developing and executing key strategic acquisitions and licensing arrangements which target revenue growth. Harry currently leads Scientia, which includes the management of consulting teams, new business development, and intellectual capital development. His client engagements have involved comprehensive go-to-market plans in the areas of diagnostics, genomic, proteomics, cell biology, cellular therapy and consumables & services groups. Scientia’s clients range from emerging innovators to global market leaders.